Search clinical trials for: ACT-541468 10 mg

Total 1428 results

Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany, Spain, Hungary, Israel, Sweden
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects

Healthy

Czechia
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study of the Way the Body Takes up, Distributes, and Gets Rid of ACT-541468 in Subjects With Abnormal Kidney Function Compared to Healthy Subjects

Healthy | Renal Insufficiency

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea

Obstructive Sleep Apnea

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Effects of Daridorexant on Nighttime Breathing in Patients With Shallow or Paused Breath During Sleep

Obstructive Sleep Apnea of Adult

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

Insomnia Disorder

United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Germany
Idorsia Pharmaceuticals Ltd.

Completed

A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects

Healthy Subjects

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Drug-drug Interactions Between ACT-541468 and Ethanol in Healthy Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
M.D. Anderson Cancer Center
Theravance Biopharma

Completed

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

Bacteremia | Infection

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Healthy Subjects

United Kingdom
Idorsia Pharmaceuticals Ltd.

Completed

A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects

Healthy

Netherlands
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Acute Myocardial Infarction

Switzerland, Israel, Belgium
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

Healthy

Germany
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Pharmacokinetics & Food Effect of MK-0941 in Adults With Type 2 Diabetes (MK-0941-009)

Type 2 Diabetes Mellitus
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Withdrawn

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease. (INSPIRE-CKD)

Hypertension | Renal Insufficiency, Chronic
Idorsia Pharmaceuticals Ltd.

Completed

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

Healthy

United States
Vedic Lifesciences Pvt. Ltd.

Not yet recruiting

A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections

Upper Respiratory Tract Infections

India
Actelion

Terminated

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients (DUAL-2)

Digital Ulcers

Spain, United States, Argentina, China, Ireland, Colombia, Israel, New Zealand, Germany, Belgium, Portugal, Netherlands, South Africa, Greece, Mexico, Poland, Puerto Rico, Russian Federation, Turkey, Ukraine, United Kingdom
Ferring Pharmaceuticals

Completed

Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

United States, Belgium, Canada, Czech Republic, Hungary, Poland, Slovakia, South Africa, Sweden, United Kingdom
Organon and Co

Completed

A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Eisai Inc.

Completed

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Idiopathic Thrombocytopenic Purpura

United Kingdom
NewAmsterdam Pharma
Veranex

Recruiting

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Pfizer

Completed

A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling

Healthy

United States
Vigonvita Life Sciences

Completed

Evaluate the Effect of TPN171H on the QT/QTc Interval in Healthy Volunteers

Healthy Subjects

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Xenon Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

Major Depressive Disorder

United States
Eisai Inc.

Completed

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

Healthy Volunteers

United States
Midnight Pharma, LLC

Completed

Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia

Chronic Primary Insomnia

United States
Natrogen Therapeutics International, Inc

Unknown

Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009)

Psoriasis
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
Firas El Chaer, MD

Recruiting

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

Hematologic Malignancy | Platelet Refractoriness

United States

3

Subscribe